Alkermes (NASDAQ:ALKS) Updates FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.030-1.210 for the period, compared to the consensus earnings per share estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Alkermes Stock Performance

Shares of NASDAQ ALKS traded down $0.11 during mid-day trading on Friday, hitting $35.89. The stock had a trading volume of 2,626,767 shares, compared to its average volume of 1,335,446. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The company has a 50 day moving average of $30.31 and a two-hundred day moving average of $28.73. Alkermes has a twelve month low of $22.90 and a twelve month high of $36.25. The firm has a market cap of $5.81 billion, a PE ratio of 18.41, a PEG ratio of 1.83 and a beta of 0.49.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Research analysts predict that Alkermes will post 2.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALKS has been the topic of several analyst reports. Mizuho increased their price target on Alkermes from $35.00 to $40.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Stifel Nicolaus raised Alkermes from a "hold" rating to a "buy" rating and increased their price target for the stock from $25.00 to $36.00 in a research report on Tuesday, November 5th. StockNews.com raised Alkermes from a "buy" rating to a "strong-buy" rating in a research report on Thursday. Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price target (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Finally, Cantor Fitzgerald cut their price target on Alkermes from $48.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Alkermes has an average rating of "Moderate Buy" and an average target price of $37.25.

Insider Transactions at Alkermes

In other news, SVP Christian Todd Nichols sold 5,208 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the transaction, the senior vice president now directly owns 60,703 shares in the company, valued at $1,769,492.45. The trade was a 7.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Cato T. Laurencin sold 2,691 shares of the business's stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the transaction, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. This represents a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 323,608 shares of company stock worth $10,854,725 in the last ninety days. Insiders own 4.89% of the company's stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.